Combination Gemcitabine and Docetaxel Therapy in Advanced Adenocarcinoma of the Pancreas

Publisher： Karger

E-ISSN： 1423-0232|60|4|316-321

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.4, 2001-06, pp. : 316-321

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298)

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 303-309

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite

Phase I Dose-Finding Study of Vandetanib in Combination with Gemcitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

By  

Oncology, Vol. 81, Iss. 1, 2011-09 ,pp. : 50-54

Karger

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite

Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer

By  

Oncology, Vol. 77, Iss. 1, 2009-06 ,pp. : 49-52

Karger

Access to resources Recommend Favorite